Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Director/PDMR Shareholding

16 Mar 2006 15:18

Flying Brands Limited16 March 2006 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS 1. Name of the issuer Flying Brands Limited 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4R(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) (i) 3. Name of person discharging managerial responsibilities/director a) M T N Dugdale b) GH Norton c) J McDowell 4. State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person N/A 5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest N/A 6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares N/A 7. Name of the registered shareholder(s) and, if more than one, the number of shares held by each of them N/A 8. State the nature of the transaction N/A 9. Number of shares, debentures or financial instruments relating to shares acquired N/A 10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) N/A 11. Number of shares, debentures or financial instruments relating to shares disposed N/A 12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) N/A 13. Price per share or value of transaction N/A 14. Date and place of transaction N/A 15. Total holding following notification and total percentage holding following notification (any treasury shares of that class should not be taken into account when calculating percentage) N/A 16. Date issuer informed of transaction N/A If a person discharging managerial responsibility has been granted options by the issuer complete the following boxes 17. Date of grant 16th March 2006 18. Period during which or date on which it can be exercised 16th March 2009 to 16th March 2016 19. Total amount paid (if any) for grant of the option Nil 20. Description of shares or debentures involved (class and number) a) M T N Dugdale - 99,589 Units b) GH Norton - 64,411 Units c) J McDowell - 39,637 Units Units comprise one ordinary share of one pence and one ordinary share of 0.005 pence21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise £2.0183p 22. Total number of shares or debentures over which options held following this notification Total number of options now held is: a) M T N Dugdale - 580,883 Units b) GH Norton - 168,984 Units c) J McDowell - 39,637 Units Units comprise one ordinary share of one pence and one ordinary share of 0.005 pence 23. Any additional information 24. Name of contact and telephone number for queries Graham Norton 01376 575081 Name and signature of duly authorised officer of issuer responsible for making notification Graham Norton, Group Finance Director Date of Notification 16th March 2006 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.